What is the appropriate dosage of linezolid for treating MRSA infection in adults and children, including route, frequency, duration, and adjustments for renal or hepatic impairment?

Linezolid Dosing for MRSA Infections

For adults with MRSA infections, administer linezolid 600 mg PO or IV every 12 hours; for children <12 years, use 10 mg/kg/dose every 8 hours (maximum 600 mg/dose), and for children ≥12 years, use 600 mg every 12 hours. 1

Standard Dosing by Age

Adults

• 600 mg PO/IV twice daily (every 12 hours) 1
• Route: Oral or intravenous (bioavailability is 100%, so no dose adjustment needed between routes) 2
• Can be given with or without food 2

Pediatric Patients

• Children <12 years: 10 mg/kg/dose PO/IV every 8 hours, not to exceed 600 mg/dose 1
• Children ≥12 years: 600 mg PO/IV every 12 hours 1
• Neonates: Dosing varies by gestational age and postnatal age due to different clearance rates 2

Duration by Infection Type

The IDSA guidelines provide specific duration recommendations 1:

• Skin and soft tissue infections (SSTI):

  • Uncomplicated: 5-10 days
  • Complicated (cSSTI): 7-14 days

• Pneumonia: Duration not explicitly specified but typically 7-14 days based on clinical response

• Bacteremia (uncomplicated): At least 2 weeks 3

• Bacteremia (complicated): 4-6 weeks depending on extent of infection 3

• Osteomyelitis: Minimum 8 weeks 3

• Septic arthritis: Duration based on clinical response with drainage

• CNS infections:

  • Meningitis: 2 weeks 3
  • Brain abscess/epidural abscess: 4-6 weeks 3

Renal Impairment Adjustments

No dose adjustment is required for renal impairment based on FDA labeling, as linezolid pharmacokinetics are not altered by renal dysfunction 2. However, recent evidence suggests more nuanced dosing:

• Normal renal function (CrCl >80 mL/min): 600 mg every 12 hours 4
• Mild renal impairment: 600 mg every 12 hours 4
• Moderate renal impairment (CrCl 30-80 mL/min): Consider 450 mg every 12 hours 4, 5
• Severe renal impairment (CrCl 10-30 mL/min): Consider 300 mg every 12 hours 4, 5
• Augmented renal clearance: May require 600 mg every 8 hours 4

Critical caveat: While the parent drug doesn't accumulate, inactive metabolites do accumulate in renal dysfunction 2. The clinical significance is unknown, but this increases toxicity risk, particularly thrombocytopenia. Low body weight patients with renal dysfunction have substantially higher risk (90% had Cmin >8 mg/L at standard dosing) 5.

Hemodialysis: Linezolid should be given after dialysis, as approximately 30% is removed during a 3-hour session 2

Hepatic Impairment

No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B) 2. Severe hepatic impairment has not been studied.

Important Safety Considerations

Therapeutic Drug Monitoring

Target trough concentrations (Cmin): 2.6-7.8 mg/L for optimal efficacy while minimizing toxicity 4

Toxicity threshold: Cmin >8 mg/L associated with increased risk of adverse events, particularly thrombocytopenia 4, 5

Key Adverse Events

• Thrombocytopenia: Risk increases with duration >2 weeks and elevated trough levels
• Nephrotoxicity: Occurs in 8.4% (vs 18.2% with vancomycin) 6
• Peripheral neuropathy and optic neuropathy: With prolonged use
• Serotonin syndrome: Linezolid is a reversible MAO inhibitor 2

Drug Interactions

• Rifampin: Decreases linezolid AUC by 32% and Cmax by 21%; clinical significance uncertain but may require dose adjustment 2
• Adrenergic agents: Avoid tyramine-rich foods (>100 mg); use caution with pseudoephedrine and phenylpropanolamine 2

Clinical Efficacy Evidence

Linezolid demonstrates superior clinical outcomes compared to vancomycin in specific MRSA infections:

• MRSA pneumonia: 57.6% clinical success vs 46.6% with vancomycin (p=0.042), though 60-day mortality was similar 6
• General MRSA infections: Comparable cure rates to vancomycin (73.2% vs 73.1%) 7
• Pediatric MRSA: 94.1% clinical cure rate vs 90% with vancomycin 8

The advantage of linezolid is most pronounced in pneumonia and CNS infections due to excellent tissue penetration (saliva:plasma ratio 1.2:1) 2, whereas vancomycin has poor lung penetration.

Practical Algorithm for Dosing

1. Determine patient age and weight

   • Adults/children ≥12 years → 600 mg q12h
   • Children <12 years → 10 mg/kg q8h (max 600 mg)

2. Assess renal function

   • CrCl >30 mL/min → Standard dosing
   • CrCl <30 mL/min AND low body weight → Consider dose reduction to 300-450 mg q12h with TDM

3. Plan duration based on infection site (see above)

4. Monitor for toxicity:

   • Baseline and weekly CBC for thrombocytopenia
   • Consider TDM if treatment >7-10 days, renal dysfunction, or low body weight
   • Target Cmin 2.6-7.8 mg/L

5. Adjust based on TDM results:

   • Cmin <2.6 mg/L → Increase dose or frequency
   • Cmin >8 mg/L → Decrease dose or extend interval